ERBB2 and breast cancer: Despite these limitations, our preliminary findings contributed to a deeper understanding of HR-low/HER2-negative BC, and future studies are needed to validate and expand our findings through more rigorous data verification processes, larger cohorts, and extended follow-up periods.